Salud
Dual Agonists for Management of Metabolic Dysfunction–Associated Steatohepatitis
![](https://univciencia.com/wp-content/uploads/2024/05/rt-ultimo4-MEZPMQ.jpeg)
Metabolic dysfunction–associated steatohepatitis (MASH) is the most common liver disease worldwide, and its prevalence is increasing rapidly.1 Yet, effective treatments for MASH remain scarce. Obesity plays a central role in MASH. Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging as the most promising antiobesity treatments2 and could…
The New England Journal of Medicine: Search Results in Gastroenterology